Compare Mercadolibre Inc (MELI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Mesoblast Limited — how do they compare? Mercadolibre Inc trades at $1,817 (market cap $92.90B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Mercadolibre Inc is far larger — about 42.8× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Mercadolibre Inc nearer its low. Which is the better fit depends on your goals.
| MELI | MESO | |
|---|---|---|
Market Cap | $92.90B | $2.17B |
Sector | Consumer Cyclical | Technology |
52-Week High | $2.51K | $20.96 |
52-Week Low | $1.55K | $12.88 |
Enterprise Value | $99.79B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,822.65, up 0.48% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with key resistance near $1,833, while recent earnings have missed expectations for three consecutive quarters. Revenue growth remains robust, reaching $28.89 billion in 2025, though net income margins have moderated. Analyst sentiment is strongly positive with a $2,220 consensus price target, but institutional selling and an ongoing legal investigation present near-term headwinds.
The outlook for MELI balances strong long-term growth potential in Latin American e-commerce and fintech against near-term margin pressure and execution risks. Investment appeal hinges on the company's ability to translate top-line expansion into sustained profitability, while key risks include competitive intensity, credit quality concerns, and macroeconomic volatility in core markets.
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
